Your session is about to expire
← Back to Search
LNP023 for Membranous Glomerulonephritis
Study Summary
This trial will compare LNP023 to rituximab to see if LNP023 is more effective and safe in treating MN.
- Membranous Glomerulonephritis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 97 Patients • NCT04558918Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the approximate number of participants engaged in this research project?
"Affirmative. The clinicaltrials.gov listings indicate that recruitment for this research has started and is ongoing, with the original posting dating back to November 23rd 2019. There are currently 4 sites searching for a total of 52 participants."
Are there any openings in this medical investigation that would accommodate a new participant?
"Clinicaltrials.gov verifies that this medical experiment is actively engaging participants. It was initially posted on the 23rd of November 2019 and the most recent iteration occurred on 18th of November 2022."
In which geographical areas is the trial being conducted?
"This clinical trial is presently being conducted in 4 different cities: Cleveland, New york, Temple and more. It would be beneficial to choose the closest medical centre for you to minimize your commuting needs should you participate."
Could you provide a summary of the research done on LNP023 thus far?
"The initial trials of LNP023 took place in 1993 at the National Institutes of Health Clinical Center, 9000 Rockville Pike. 809 studies have been conducted since then; presently 415 live experiments are taking place across the nation with a significant percentage based out of Cleveland, Ohio."
What health conditions is LNP023 commonly used to treat?
"LNP023 is an efficacious therapy for the treatment of diffuse large b-cell lymphoma, in addition to conditions such as polyangium and pemphigus vulgaris."
Has the FDA approved LNP023 for therapeutic use?
"The efficacy of LNP023 is yet to be proven, thus it scored a 2 on our team's safety scale. This Phase 2 trial has yielded some reassuring data regarding the drug's security profile."
Share this study with friends
Copy Link
Messenger